{
  "ticker": "NGNE",
  "company_name": "Neurogene Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04659629",
      "title": "NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Advanced Solid Tumor",
      "start_date": "2021-04-26",
      "completion_date": "2024-08-15",
      "enrollment": 0,
      "sponsor": "Neurogene Inc."
    },
    {
      "nct_id": "NCT05228145",
      "title": "Gene Therapy Study for Children With CLN5 Batten Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Neuronal Ceroid Lipofuscinosis CLN5",
      "start_date": "2022-01-31",
      "completion_date": "2028-11",
      "enrollment": 0,
      "sponsor": "Neurogene Inc."
    },
    {
      "nct_id": "NCT03853876",
      "title": "A Natural History Study of Aspartylglucosaminuria",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency, Lysosomal Storage Diseases",
      "start_date": "2019-04-18",
      "completion_date": "2022-03-17",
      "enrollment": 0,
      "sponsor": "Neurogene Inc."
    },
    {
      "nct_id": "NCT03822650",
      "title": "A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Ceroid Lipofuscinosis, Neuronal 5",
      "start_date": "2019-03-13",
      "completion_date": "2024-05-30",
      "enrollment": 0,
      "sponsor": "Neurogene Inc."
    },
    {
      "nct_id": "NCT03810508",
      "title": "A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Charcot-Marie-Tooth Disease, Hereditary Motor and Sensory Neuropathy IV",
      "start_date": "2019-07-18",
      "completion_date": "2022-02-15",
      "enrollment": 0,
      "sponsor": "Neurogene Inc."
    },
    {
      "nct_id": "NCT05898620",
      "title": "A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Rett Syndrome",
      "start_date": "2023-06-13",
      "completion_date": "2029-12",
      "enrollment": 0,
      "sponsor": "Neurogene Inc."
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE1": 1,
      "PHASE1, PHASE2": 1,
      "": 3,
      "PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "TERMINATED": 2,
      "RECRUITING": 1
    },
    "active_trials": 2,
    "completed_trials": 2,
    "conditions": [
      "Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency, Lysosomal Storage Diseases",
      "Ceroid Lipofuscinosis, Neuronal 5",
      "Charcot-Marie-Tooth Disease, Hereditary Motor and Sensory Neuropathy IV",
      "Neuronal Ceroid Lipofuscinosis CLN5",
      "Rett Syndrome",
      "Solid Tumor, Advanced Solid Tumor"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:17.086116",
    "search_query": "Neurogene Inc.",
    "url": "https://clinicaltrials.gov/search?term=Neurogene+Inc."
  }
}